New cell-string optimizer technology from Maxim Integrated Products, Inc. (NASDAQ: MXIM) allows photovoltaic (PV) panels to harvest significantly more energy and simplifies design complexity for solar installation projects.
Maxim’s cell-string optimizers are highly integrated DC-DC converters that replace the bypass diode and perform maximum power point tracking (MPPT) deep inside the PV module. By replacing each diode with a MPPT device, the on-off response to performance mismatch is eliminated; every cell-string contributes maximum power without interfering with the power production capability of others. This enhanced degree of flexibility leads to increased energy production; eliminating collateral performance loss due to module mismatch, degradation, soiling, localized shading, and row shading loss mechanisms.
Based on the company’s industry leading power semiconductor technology, Maxim’s cell-string optimizer is the first integrated power IC to perform MPPT and first to be embedded within the PV module.
Key Advantages
Commentary
“The granularity of Maxim’s cell-string optimizers offers best-in-class shade mitigation, enables flexible system design without adding complexity, and helps improve panel lifetime performance,” said Seth Kahn, Executive Director, Solar Products, Maxim Integrated. “Major PV module companies have recognized the advantages of this unique technology—the first integrated power semiconductor for MPPT—and are ramping it in volume production.”
Tower Semiconductor announced that it has signed silicon photonics agreements valued at $1.3 billion for…
The report is based on a survey of 150 CISOs and senior cybersecurity leaders from…
More than 200,000 voters will cast ballots using a secure and cryptographically verified online voting…
The multi-center study, involving 2,000 patients, will validate the CORA system - a breakthrough AI…
Molex, a global electronics leader and connectivity innovator, has completed the acquisition of Teramount Ltd.,…
This agreement marks the third expansion of its collaboration with AstraZeneca, building on collaborations in…